Rotavirus vaccine side effects: RotaTeq vs Rotarix, VAERS data, trials and schedule
This page answers “rotavirus vaccine side effects” with sourced pharmacovigilance data — intussusception signal with VAERS category view. Counts are database reports, not proven vaccine-caused injury rates.
How to read database counts: Pharmacovigilance systems (VAERS, EudraVigilance, Yellow Card, VigiBase, Lareb, DAEN) collect spontaneous, unverified reports. A report is not a confirmed adverse event and does not prove the vaccine caused the outcome. Under-reporting, stimulated reporting, and missing denominators limit rate interpretation. Compare with trials and epidemiological studies on each page before drawing conclusions.
Gold Standard EO (Aug 10, 2026)Federal recommendation status: Based on shared clinical decision-making
The August 10, 2026 Executive Order on Gold Standard Childhood Vaccine Recommendations places rotavirus in the Based on shared clinical decision-making category — not a universal recommendation for all children. The EO also expresses a preference, to the maximum extent feasible, for administering all childhood immunizations at separate medical visits.
This page summarizes published data for rotavirus vaccines on the U.S. childhood schedule (RotaTeq®, RV5 and Rotarix®, RV1). Both are live attenuated oral vaccines. A prior rotavirus vaccine (RotaShield®, 1998) was withdrawn in 1999 due to an association with intussusception (~1 per 10,000 doses). This history is context for the extensive safety surveillance of current products. Data are presented without interpretive language that implies the vaccine is "safe" or "unsafe."
Evidence state
For each outcome: the specific question, what controlled studies found, and how certain that evidence is on the GRADE scale (high, moderate, low, very low). Ratings are editorial judgments by the site applying GRADE to the studies in the table below — observational evidence starts at low and is rated up for large, consistent effects or a dose/age gradient, and down for inconsistency or imprecision (Methods). Where an effect is confined to a subgroup (for example young males), the question says so. "Not searched" means no controlled study has been compiled here yet; it is not a finding that the outcome is rare or caused by the vaccine.
Outcome & question
Finding & certainty
Why this rating
Intussusception
RotaTeq (RV5) and Rotarix (RV1), week after dose 1
increased risk (about 1–5 extra cases per 100,000 vaccinated infants, mostly in the week after the first dose) High certainty
Start low; +2 very large effect after dose 1 (relative incidence ≈ 5) replicated in the US, Mexico and Brazil. Randomized trials were too small for an event this rare (pooled RR 1.14, 0.49–2.64): imprecise, not contradictory. Studies: Yih 2014, Weintraub 2014, Patel 2011, Shui 2012, Lu 2019.See table
Anaphylaxis
Not searched
No controlled-study result is compiled for this outcome yet.
Myocarditis or pericarditis
Not searched
No controlled-study result is compiled for this outcome yet.
Guillain-Barré syndrome
Not searched
No controlled-study result is compiled for this outcome yet.
Febrile seizure
Not searched
No controlled-study result is compiled for this outcome yet.
Immune thrombocytopenia
Not searched
No controlled-study result is compiled for this outcome yet.
1. Basic Information
Disease Protected Against
Rotavirus is the leading cause of severe acute gastroenteritis in infants and young children globally. Before vaccination, rotavirus caused ~2.7 million cases of gastroenteritis, ~400,000 physician visits, ~70,000 hospitalizations, and ~20–60 deaths annually in U.S. children <5. Globally, rotavirus caused ~215,000 deaths/year in children <5 (pre-vaccine), predominantly in low-income countries. Transmission is fecal-oral. Almost all children are infected by age 3–5, regardless of sanitation quality.
CDC Schedule (U.S., 2025)
Dose
Recommended Age
Notes
Dose 1
2 months
Minimum age 6 weeks; maximum age for dose 1 = 14 weeks 6 days
Dose 2
4 months
Minimum interval 4 weeks
Dose 3 (RotaTeq only)
6 months
RotaTeq (RV5) requires 3 doses; Rotarix (RV1) requires 2 doses. All doses must be completed by 8 months 0 days.
Source: CDC ACIP, 2025 schedule. The strict age window (must start by 14w6d, must finish by 8m0d) is due to a small background risk of intussusception in older infants unrelated to vaccination.
Licensed Rotavirus vaccine products
Each product has its own page with package-insert ingredients, side-effect data, lot lookup and comparisons with the other brands.
Structured composition for 2 branded products covered on this page,
taken from FDA-approved package inserts (DailyMed / manufacturer prescribing information).
Lists are per product — formulations differ by manufacturer and presentation.
Click an ingredient name to open its safety-context page when available.
Live attenuatedOralNo preservative (typical single-dose)Polysorbate 80
RotaTeqMerck Sharp & Dohme LLC · Live attenuated
Delivery
Route: Oral
Form: Oral solution
Dose volume: 2 mL
Presentation: single-dose ready-to-use oral tube
Encapsulation / delivery vehicle
None (no nanoparticle/VLP encapsulation system)
Antigens
Antigen
Type
Amount / dose
Live reassortant rotavirus G1
Live attenuated virus
≥2.2 × 10^6 infectious units
Live reassortant rotavirus G2
Live attenuated virus
≥2.8 × 10^6 infectious units
Live reassortant rotavirus G3
Live attenuated virus
≥2.2 × 10^6 infectious units
Live reassortant rotavirus G4
Live attenuated virus
≥2.0 × 10^6 infectious units
Live reassortant rotavirus P1A[8]
Live attenuated virus
≥2.3 × 10^6 infectious units
Adjuvants
None listed on the package insert for this product (common for live attenuated and some inactivated whole-virus vaccines).
Preservatives
None — Single-dose presentation; label states no preservative.
Ingredient lists are sourced from official package inserts for the specific brands named above.
Formulations can change between lots and over time — verify against the current label before any clinical decision.
Presence of a substance does not by itself indicate harm; toxicology is dose-, route-, and context-dependent.
Browse the full ingredient database:
Vaccine Ingredients index.
Causality assessment & potential mechanisms
Conditions below combine WHO-style causality levels with potential biological mechanisms
from the site mechanism catalog
(ae_mechanisms_catalog.json).
HRSA VICP table listing (where shown) indicates a compensable temporal association under U.S. program rules —
not automatic proof of causation for every case. Mechanisms are hypothesis-level pathways with graded evidence.
Condition
Time window
Causality
Potential mechanism(s)
IntussusceptionHRSA table
1–21 days
Very likely / Probable
Evidence: High
Intussusception after oral rotavirus vaccine (primary · innate_inflammation)
Oral rotavirus vaccines can promote lymphoid hyperplasia and altered gut motility that rarely lead to telescoping of intestine (intussusception), especially after dose 1.
Framework: WHO causality + HRSA VICP (where applicable) + AE mechanism catalog.
Last updated: 2026-07-18.
Schema: schemas/vaccine_injury_table.schema.json
· Mechanisms: schemas/ae_mechanism.schema.json.
Not medical or legal advice.
2. Pre-Licensure Clinical Trial Data
Licensure trial design (ICAN / OpenVAERS)
The table below reproduces ICAN’s No Placebo Table rows for U.S. childhood-schedule products relevant to this page — including the control/comparator used in FDA licensing trials (not always saline placebo). OSMF presents this for transparency; it is not an endorsement of ICAN interpretations.
Vaccine
Brand
Manufacturer
Doses (schedule)
Ages injected
Control / comparator
Placebo
Safety review window
RV2
Rotarix
GSK
2 or 3
2M 4M 6M
Dextran, Sorbitol, Amino Acids, Dulbecco’s Modified Eagle Medium, and Xanthan
No
31 days + 1 year for intussusception
RV2
RotaTeq
Merck
2 or 3
2M 4M 6M
Polysorbate-80, Tissue Culture Medium, Fetal Bovine Serum, and Sodium Phosphate
No
42 days + 1 year for intussusception
Source: OpenVAERS — No Placebo Table · ICAN original PDF
· Attribution: Informed Consent Action Network (ICAN) via OpenVAERS
· Last fetched: 2026-07-16.
For many trials listing '6 months' safety review, ICAN notes review was typically ~30 days post-injection with a phone call at 6 months.
Current rotavirus vaccines were developed with intussusception safety specifically in mind, following the RotaShield experience. Both RotaTeq and Rotarix conducted very large pivotal trials.
Metric
RotaTeq (RV5, Merck)
Rotarix (RV1, GSK)
Pivotal trial size
~70,000 infants (REST trial); ~35,000 received RotaTeq
~63,000 infants; ~31,500 received Rotarix
Efficacy against severe rotavirus gastroenteritis
~98% (U.S./Europe); lower in low-income settings (~50–65%)
~85–96% (high-income); lower in low-income settings (~50–65%)
Efficacy against any rotavirus hospitalization
~96%
~85–96%
Intussusception (pre-licensure)
No signal observed vs. placebo within 42 days (6 cases vs. 5 cases in placebo)
No signal observed vs. placebo within 31 days
The REST (RotaTeq) and Rotarix pivotal trials are the largest pre-licensure vaccine trials ever conducted, with ~130,000+ infants combined. Both were specifically powered to evaluate intussusception risk.
Most Common Adverse Reactions
Reaction
RotaTeq / Rotarix (Approx.)
Diarrhea
~10–20% (mild, self-limited)
Vomiting
~8–15%
Irritability
~15–25%
Fever
~10–20%
Adverse reactions are generally mild and self-limited (1–3 days). Rates are comparable to placebo in the large trials, reflecting the high background rate of these symptoms in infants.
Key Limitations
Intussusception at very low rates: Even the very large pivotal trials (N=130,000+) were not adequately powered to detect intussusception at rates of ~1–5 per 100,000 doses. This risk was identified and quantified post-licensure.
Lower efficacy in low-income countries: Rotavirus vaccine efficacy is substantially lower in low-income settings, a phenomenon also observed with oral polio vaccine but not fully understood. Possible contributing factors include maternal antibody interference, gut microbiome differences, and malnutrition.
Contraindication in SCID: Infants with severe combined immunodeficiency (SCID) can develop severe, prolonged vaccine-strain rotavirus gastroenteritis. SCID is now screened at birth in the U.S., allowing identification before the 2-month vaccination visit.
3. Post-Licensure Safety Data
Intussusception — Confirmed Post-Licensure Signal
Post-licensure VSD and international studies identified a small but statistically significant increased risk of intussusception following rotavirus vaccination, primarily in the 3–7 day window after the first dose.
RotaTeq (RV5): Estimated ~1–1.5 excess cases of intussusception per 100,000 first doses (VSD data). Attributable fraction small relative to background risk of intussusception (~35 per 100,000 infant-years).
Rotarix (RV1): Estimated ~1–5 excess cases per 100,000 first doses (international studies; higher estimates from some datasets).
Risk-benefit: Studies estimate that rotavirus vaccination prevents ~50,000–70,000 U.S. hospitalizations annually while causing ~40–120 excess intussusception cases. The benefit-risk ratio is estimated at approximately 500–1,000 hospitalizations prevented per excess intussusception case.
The intussusception risk is acknowledged by ACIP, CDC, and WHO, and is included in product labeling. IOM (2012) concluded evidence favors acceptance of a causal relationship for rotavirus vaccine and intussusception.
Other Post-Licensure Findings
Horizontal transmission: Vaccine-strain rotavirus can be shed in stool and transmitted to unvaccinated contacts. This is generally considered a benefit (indirect protection) but can cause disease in severely immunocompromised contacts.
Porcine circovirus (PCV) contamination: In 2010, both RotaTeq and Rotarix were found to contain DNA fragments of porcine circovirus (PCV-1 and PCV-2). FDA determined this did not pose a safety risk, and vaccination continued. PCV is not known to cause disease in humans.
⚠ Critical Caveat
VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event.
VAERS reports per million doses
U.S. VAERS reports for vaccinations given 2006–2024, divided by the 167 million doses distributed in the same years (HRSA, from CDC data).
All reports
157
per million doses (155–159) · 26,214 reports
Serious reports
27.9
per million doses · 4,665 reports (death, life-threatening, hospitalised or disabled)
Reports with a death
4.08
per million doses · 682 reports
These are reporting rates: they mix real reactions, coincidental events and reports of conditions that would have happened anyway, and they depend on how actively each vaccine is watched. Doses are distributed, not administered. Combination vaccines count toward each component in both numerator and denominator. Compare with the observed-vs-expected analysis and the controlled studies above. Data: vaers_reporting_rates.json.
All vaccines, per million doses
Vaccine
All
Serious
Death
pcv
266
28.1
3.23
rotavirus
157
27.9
4.08
hpv
335
25.3
2.00
hib
126
19.7
3.25
polio
152
17.6
2.77
mmr
320
15.3
0.94
varicella
372
14.1
0.84
hepatitis-b
110
12.7
2.15
meningococcal
214
11.8
0.70
dtap
132
11.2
1.31
hepatitis-a
152
8.5
0.58
influenza
68
5.4
0.48
What controlled safety studies found
Unlike VAERS counts, these studies compare vaccinated people with a control group or control time window, so they can estimate whether a risk is raised and by how much. 8 results for rotavirus vaccines: 4 found an increased risk of a specific outcome, 3 found no increased risk.
Outcome
Design & population
Estimate (95% CI)
Excess per million doses
Finding
Source
Intussusception
Rotarix (RV1)
cohort, sequential vs historical and vs concurrent RV5 recipients (VSD) Infants 4-34 wk, US (207,955 RV1 doses)
Trials on ClinicalTrials.gov with posted results and a placebo, saline or no-vaccine control arm (55,641 vaccinated vs 48,615 controls), pooled with a random-effects model:
Any serious adverse event: RR 0.86 (95% CI 0.80–0.91), 13 trials, I² 0% — less frequent with vaccine
Death (any cause, including from the disease itself): not estimable
by product — RotaTeq: RR 0.90 (95% CI 0.83–0.98), 6 trials, I² 0% — less frequent with vaccine
by product — Rotarix: RR 0.79 (95% CI 0.69–0.89), 7 trials, I² 14% — less frequent with vaccine
Rotavirus gastroenteritis that leads to hospitalisation is itself recorded as a serious adverse event, so a vaccine that prevents it shows fewer serious events than placebo.
Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines
10/463
4/155
Only blinded, placebo-controlled periods are used (open-label, crossover, booster and extension periods excluded) and vaccine and placebo arms are matched within the same trial part. Risk ratios use participant counts, not person-time: where placebo recipients crossed over to vaccine, the placebo arm is followed for less time, which pushes count-based ratios up. Serious adverse events are sponsor-coded and include events unrelated to vaccination; trials were powered for efficacy, not rare harms; most childhood-vaccine trials use active comparators and therefore do not appear here. Code: analysis/vaccine_trial_meta.py; data: vaccine_trial_meta.json.
When do reported events start? (time to onset)
Days from vaccination to onset in U.S. VAERS reports (0–180 days). A causal reaction usually starts inside a characteristic window; but people also report what happens soon after a shot, so each event is compared with all other reports for this vaccine. The Weibull shape measures bunching (below 1 = most onsets early).
Event
Reports
Median days
In risk window
Shape (95% CI) vs others
Reading
Intussusception
1,286
8
63% (others 29%)
0.82 (0.80–0.85) vs 0.66
spread later than other reports
Seizure (any)
781
1
96% (others 97%)
0.69 (0.64–0.74) vs 0.66
same timing as other reports
Febrile seizure
152
1
97% (others 97%)
0.69 (0.61–0.89) vs 0.66
same timing as other reports
Sudden infant death
104
3
73% (others 95%)
0.93 (0.86–1.04) vs 0.66
spread later than other reports
Kawasaki disease
69
10
74% (others 30%)
0.77 (0.67–0.93) vs 0.66
same timing as other reports
Syncope
41
0
73% (others 83%)
0.53 (0.45–0.76) vs 0.66
same timing as other reports
ADEM / encephalitis
21
0
38% (others 30%)
0.52 (0.44–0.69) vs 0.66
same timing as other reports
Timing alone cannot establish causation; it can make it more or less plausible. *Fitted on a random sample of 5,000 of these reports. Data: vaers_onset.json.
VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE
The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (Rotavirus (RotaTeq + Rotarix combined)):
Metric
Value
U.S. doses administered (2006–2022)
150,866,652
Total VAERS AE reports
19,899
AE reporting rate (per 100,000 doses)
13.2
Total death reports
476
Death reporting rate (per 100,000 doses)
0.316
AE-to-Death ratio
42:1
Source: Halma, M.; Varon, J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4020007. CC BY 4.0. Data from Table 1.
📚 Important Interpretive Caveats (from the paper itself)
Reporting rate ≠ incidence rate. VAERS is a passive, unverified system. A report means someone submitted a claim of temporal association, not a confirmed causal event. The paper is explicit that causality cannot be inferred from these numbers alone.
Reporting behavior is not uniform. More serious, unusual, or media-salient events are reported at much higher rates than mild ones. Products receiving more public, media, legal, and clinical attention (particularly COVID-19 vaccines, which also benefited from V-safe active-surveillance prompts and CICP compensation pathways) generate more reports per dose regardless of true risk.
Age and comorbidity confounding is not adjusted. COVID-19 vaccines were disproportionately administered to elderly and comorbid populations (nursing homes, 65+, high-risk groups in early 2021) with much higher background all-cause mortality than the general child/working-age population. Some fraction of temporally-associated deaths would occur regardless of vaccination, and the paper does not perform a background-rate comparison.
Stimulated reporting is a known, documented phenomenon. Media coverage, plaintiff attorney solicitation, and advocacy campaigns — all independently inflate VAERS reporting propensity. The paper cites this literature but does not correct for it.
Small-denominator rows are unreliable. Rates computed from small denominators (e.g., monovalent measles, DT, mumps, rubella) have enormous statistical uncertainty and should not be compared to vaccines with hundreds of millions of administered doses without noting the wide confidence intervals.
Source: Halma, M.; Varon, J. DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines. Pharmacoepidemiology. 2025, 4, 7. DOI: 10.3390/pharma4020007. CC BY 4.0.
Passive Surveillance: AE Type Breakdown (Multi-System)
Side-by-side view of U.S. VAERS, Health Canada Canada Vigilance, Japan JADER (PMDA), EU EudraVigilance, and live-scraped international systems via SurVigilance (VigiAccess, Lareb, DAEN, DMA, Medsafe). SurVigilance panels show MedDRA PT mention totals (not individual-case counts). Category assignment uses keyword matching — approximate, not official SOC coding. VAERS files on this site are built from the public VAERS download. FAERS figures use the public quarterly FAERS files. Counts are mentions or reports, not incidence.
VAERS (United States)
Canada Vigilance (Canada)
JADER (PMDA, Japan)
EudraVigilance (EU)
No matching vaccine cases in the current EudraVigilance DAP export.
This system’s totals are not in this panel. Published counts, when this site has them, are in the surveillance section.
DMA (Denmark)
Denmark DMA interactive ADR search is currently offline (Danish Medicines Agency IT transition; public overviews frozen at 12 Mar 2024). Live product PT tables cannot be retrieved until DKMA restores the search. See DKMA notice. Denmark continues to report into EU EudraVigilance (panel above).
Medsafe (New Zealand)
VAERS (U.S., 2006–2024): 25,405 symptom mentions (5.61/100k doses). Largest share: Other / Unclassified (74%), Gastrointestinal (11%), General / Systemic (non-local) (4%). Canada Vigilance (CV Online extract): 187 reaction mentions in 65 unique reports (84.6% serious (55 of 65 reports)). Largest share: Gastrointestinal (28%), Thrombotic / Hematological (9%), General / Systemic (non-local) (8%). JADER (PMDA public CSV extract): 2,763 reaction mentions in 1,217 unique reports (0.7% serious (8 of 1,217 reports)). Largest share: Gastrointestinal (46%), Other / Unclassified (37%), General / Systemic (non-local) (7%). VigiAccess (WHO): 250,075 reaction-term mentions · search: rotavirus. Largest share: Other / Unclassified (26%), Gastrointestinal (20%), General / Systemic (non-local) (15%). Lareb (Netherlands): 3,974 reaction-term mentions · search: Rotavirus vaccine. Largest share: Gastrointestinal (34%), General / Systemic (non-local) (26%), Other / Unclassified (18%). Medsafe (New Zealand): 1,120 reaction-term mentions · search: rotavirus. Largest share: Gastrointestinal (47%), Other / Unclassified (14%), General / Systemic (non-local) (13%). Cross-database note: All systems are passive and unverified; reporting rates are not directly comparable across countries (different populations, reporting incentives, and lack of dose denominators for Canada/Japan/EU). top VAERS: Other / Unclassified; top Canada Vigilance: Gastrointestinal; top JADER: Gastrointestinal. SurVigilance note: VigiAccess, Lareb, DAEN, DMA, and Medsafe counts are live-scraped MedDRA PT mention totals (not deduplicated individual cases). Data via SurVigilance (GPL-3.0; pip install SurVigilance). Category assignment uses keyword matching on reported reaction terms — approximate and exploratory. Neither database establishes causality.
Pharmacovigilance Lot Signal Detection — Hypothesis-Generating Only
Multi-system context below. VAERS (U.S.) supports lot-level volume z-scores and seriousness flags by product and lot (2006–2026). Each lot links to a summary with report count, seriousness %, adverse-event pie chart, U.S. state map, and timeline. A signal flag means a statistical threshold was exceeded — not that a lot is unsafe. Full dashboard →
VAERS flags:VOL high report volume (z ≥ 3) ·
BURST clustered in <90 days ·
SER serious reports >50%.
Lot numbers are voluntary/incomplete in VAERS. Location data is U.S. state only (no postal codes in the public extract).
VAERS (United States) — all lots by product
5,886 reports with usable lot across 732 lots · 117 flagged
Loading lot tables…
Other Pharmacovigilance Systems
Lot-level analysis is only possible where reporters supply batch/lot numbers in the public extract. Canada Vigilance, JADER (PMDA, Japan), and most other national systems publish product-level spontaneous reports without lot fields.
Canada Vigilance (Health Canada)
65 unique reports · 187 reaction mentions · 84.6% serious (55 of 65 reports). Top categories: Gastrointestinal (28%), Thrombotic / Hematological (9%), General / Systemic (non-local) (8%).
Canada Vigilance spontaneous reports are unverified temporal associations. The public CV Online data extract does not include lot or batch numbers, so lot-level signal detection is not possible for this system — only product-level reaction patterns are shown here. No Canadian dose denominators are available. Extract 2026-03-31.
1,217 unique reports · 2,763 reaction mentions · 0.7% serious (8 of 1,217 reports). Top categories: Gastrointestinal (46%), Other / Unclassified (37%), General / Systemic (non-local) (7%).
JADER (Japanese Adverse Drug Event Report database) spontaneous reports are unverified temporal associations; PMDA has not assessed causality per case. The public CSV extract does not include lot or batch numbers, so lot-level signal detection is not possible — only product-level reaction patterns are shown here. Reaction terms in source data use MedDRA/J Preferred Terms. JADER CSV extract pmdacasereport202606 (2026-06). JADER reference (PDF)
Active Pharmacovigilance (Defined-Population Surveillance)
Curated findings for Rotavirus vaccines (RotaTeq / Rotarix) from active systems (not VAERS). Page inventory last reviewed: 2026-07-10.
ⓘ Active vs. passive — why this pane is separate
The VAERS / multi-system charts above are passive surveillance: spontaneous, unverified reports without a fixed denominator.
Active surveillance starts from a defined, enumerated population (EHR/claims or structured post-vaccination surveys), applies pre-specified statistical tests, and asks whether an outcome occurs
more often than expected in a risk window versus a comparison window or group.
These are not two flavors of the same evidence — active findings are the harder tier that can confirm, refute, or leave under investigation a signal first hinted in passive data.
Do not add VAERS report counts to active incidence rates.
○ No signal detected◐ Signal under investigation◑ Investigated — not confirmed● Signal confirmed (true association)– Not currently under active surveillance
CDC Vaccine Safety Datalink (VSD)
Outcome: Intussusception
Tier 2● Signal confirmed (true association)
Active surveillance confirmed a small increased risk of intussusception after current rotavirus vaccines (on the order of ~1–5 excess cases per 100,000 vaccinated infants in published estimates, product- and window-dependent). Risk is much lower than with the withdrawn RotaShield product; benefits against severe gastroenteritis remain the policy rationale for continued use.
Population
Infants receiving monovalent and pentavalent rotavirus vaccines
Risk interval
Typically 1–7 and 1–21 days after dose 1 (and additional dose windows in some analyses)
Comparison
Control intervals / unexposed person-time
Evaluation period
Post-licensure U.S. monitoring (key NEJM report 2014 for monovalent product)
Method
Active surveillance / cohort and self-controlled designs with chart validation
Related passive AE category on this page: Gastrointestinal (see multi-system charts above — not additive with active rates).
Update cadence: Tier 1: check AusVaxSafety monthly when public pages update. Tier 2/3: quarterly review around ACIP meetings and PubMed/MMWR; set lastReviewed per record.
Source tiers: Tier 1 = public near-real-time dashboards (e.g. AusVaxSafety);
Tier 2 = VSD / Sentinel / PRAC-type findings released via ACIP slides, MMWR, or papers (no public VSD raw dashboard);
Tier 3 = regulator label/safety communications.
Detecting a signal and later classifying it as not confirmed is normal system behavior — not an anomaly to hide or amplify.
4. Documented Adverse Events
Rank-aggregated VAERS signal detection (rankv)
The table below lists vaccine–event pairs that were detected as disproportionality signals by all four base methods used in rankv (GPS, PRR, ROR, BCPNN) on multi-decade VAERS data, then ordered by rank aggregation (Borda average rank; related to the Spearman/GA top-list approach in the rankv paper).
Data: ~30 years of public VAERS (rankv processed tables).
Origin: precisionFDA “Gaining New Insights by Detecting Adverse Event Anomalies” challenge solution.
Caveat: Disproportionality signals are statistical associations in spontaneous reports. They do not establish causality, incidence, or product defect. Many top pairs reflect administration/product-use coding rather than clinical injury.
Intussusception: ~1–5 excess cases per 100,000 first doses within 3–7 days post-dose 1. IOM (2012) favored acceptance of causal relationship. Background risk (~35 per 100,000 infant-years) is higher than vaccine-attributable risk. Strong
Source: CDC Pink Book; WHO. Substantial herd protection has been observed, with declines in rotavirus disease in unvaccinated older children and adults.
Disease Burden Over Time
Reported U.S. disease burden by year. The dashed vertical line marks vaccine introduction. Hover or tap data points for values; use arrow keys when a chart has focus.
ⓘ About these charts: These are accessible SVG line charts with keyboard navigation, hover tooltips, and an underlying data table (expand below). The dashed vertical line marks the year of vaccine introduction. Reported cases undercount true incidence; case definitions, reporting practices, and diagnostic methods have changed over time. See Section 5 for additional context and pre-vs-post era comparisons.
7. Evidence Summary
Rotavirus vaccines have been studied in the largest pre-licensure trials in vaccine history (N=130,000+ combined), specifically designed to evaluate intussusception risk. The post-licensure identification of a small intussusception risk (~1–5 per 100,000 first doses) is an example of the surveillance system functioning as designed—detecting a risk too small to be identified even in the very large pre-licensure trials. The benefit-risk ratio strongly favors vaccination. The primary evidence gap is the lower efficacy in low-income countries, an active area of research.
Domain
Evidence Grade
Efficacy (severe rotavirus disease, high-income)
Strong
Intussusception risk
Strong
Efficacy (low-income settings)
Moderate
8. International Surveillance & Global Data
Quick links to public pharmacovigilance databases and trial registries relevant to Rotavirus Vaccine. Reporting counts do not establish causality.
Note: Spontaneous reports are unverified observations. Compare with epidemiological studies in Sections 3–6 before drawing conclusions.
9. Curated Adverse Event Literature
Curated peer-reviewed literature linking specific adverse events to Rotavirus Vaccine. Each entry is a case report, case series, or related safety publication identified via PubMed. Expand Search PubMed for additional literature below to run custom queries.
Disclaimer: Published reports describe observations and associations; they do not establish population incidence or causality.
Common questions
How long do Rotavirus vaccine side effects last?
Most reported Rotavirus vaccine reactions are short-lived: injection-site soreness, tiredness, and low-grade fever that typically begin within a day or two and resolve within a few days. Longer-lasting or more serious events are rarer and are the ones tracked in the post-licensure surveillance and documented adverse-event sections of this page, with report counts that are not incidence rates. Anything severe or persisting beyond a week warrants medical review.
Is the Rotavirus vaccine given to adults, and are side effects different in adults?
Whether the Rotavirus vaccine is recommended for adults depends on the vaccine and the person's risk factors; the schedule and product sections above describe the licensed indications and age groups. Reporting patterns in adults can differ from children, so this page's VAERS and international database breakdowns should be read with the reporting population in mind. Check the current CDC/ACIP adult schedule and the product's prescribing information for adult dosing.
10. Key References
Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33. (REST trial; N=68,038)
Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. (Rotarix pivotal trial; N=63,225)
IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
Weintraub ES, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014;370(6):513–519.
Yih WK, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(6):503–512. (VSD study)